http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113156120-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57442 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-30 |
| filingDate | 2021-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113156120-B |
| titleOfInvention | Application of B7H4 in preparation of endometrial cancer molecular typing reagent and system |
| abstract | The method comprises the steps of screening the POLE mutant by a sequencing method; 4 kinds of mismatch repair proteins are detected on the specimen without pathogenic mutation, and a dMMR type is screened out; the specimen without dMMR utilizes immunohistochemical detection p53 protein to screen p53 mutant; the absence of the p53 mutation is judged to be NSMP type; in the samples for which the dMMR type and the NSMP type were determined, the B7H4 staining in 1% or more of the tumor cells was determined as the B7H 4-expressing type by the expression of the immunohistochemical detection protein B7H4, and the others were determined as the B7H 4-non-expressing type. Thus, endometrial cancer was classified as a pane mutant, B7H 4-expressing, B7H 4-non-expressing, and p 53-mutant. The improved molecular typing is still based on molecular pathology, has the characteristics of relative objectivity, high repeatability and clinical feasibility of the existing molecular typing, has higher prediction capability compared with the existing model, and is beneficial to avoiding over-treatment and insufficient treatment. |
| priorityDate | 2021-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.